Dyslipidemia - Pipeline Review, H2 2015 Now Available at iData Insights Dyslipidemia - Pipeline Review, H2 2015 Summary Global Markets Direct s, Dyslipidemia - Pipeline Review, H2 2015, provides an overview of the Dyslipidemia s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Dyslipidemia The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dyslipidemia and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects - A review of the Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Dyslipidemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Dyslipidemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance 1
and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=179091/dyslipidemia-pipeline-review-h2-2015 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=179091/dyslipidemia-pipeline-review-h2-2015 Table of Contents Table of Contents 2 List of Tables 7 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Dyslipidemia Overview 12 Therapeutics Development 13 Pipeline Products for Dyslipidemia - Overview 13 Pipeline Products for Dyslipidemia - Comparative Analysis 14 Dyslipidemia - Therapeutics under Development by Companies 15 Dyslipidemia - Therapeutics under Investigation by Universities/Institutes 21 Dyslipidemia - Pipeline Products Glance 22 Late Stage Products 22 Clinical Stage Products 23 Early Stage Products 24 Unknown Stage Products 25 Dyslipidemia - Products under Development by Companies 26 Dyslipidemia - Products under Investigation by Universities/Institutes 34 Dyslipidemia - Companies Involved in Therapeutics Development 35 2
Acasti Pharma Inc. 35 Allergan Plc 36 Alnylam Pharmaceuticals, Inc. 37 Amgen Inc. 38 Arbutus Biopharma Corporation 39 Arisaph Pharmaceuticals, Inc. 40 Astellas Pharma Inc. 41 AstraZeneca Plc 42 AtheroNova Inc. 43 BASF SE 44 BCWorld Pharm Co. Ltd. 45 Cadila Pharmaceuticals Ltd. 46 Cardax Pharmaceuticals, Inc. 47 Catabasis Pharmaceuticals, Inc. 48 Cerenis Therapeutics Holding SA 49 Chong Kun Dang Pharmaceutical Corp. 50 CJ HealthCare Corp. 51 Connexios Life Sciences Pvt. Ltd. 52 CymaBay Therapeutics, Inc. 53 Daewoong Pharmaceutical Co., Ltd. 54 Daiichi Sankyo Company, Limited 55 Debiopharm International S.A. 56 Eli Lilly and Company 57 3
Gemphire Therapeutics Inc. 58 Genfit SA 59 GlaxoSmithKline Plc 60 HanAll Biopharma Co., Ltd. 61 Hanmi Pharmaceuticals, Co. Ltd. 62 Huons Co., Ltd. 63 Hyundai Pharmaceutical Co., Ltd. 64 Innovent Biologics, Inc. 65 IPCA Laboratories Limited 66 Isis Pharmaceuticals, Inc. 67 Jeil Pharmaceutical Co., Ltd. 68 Jenrin Discovery, Inc. 69 JW Pharmaceutical Corporation 70 Kissei Pharmaceutical Co., Ltd. 71 Kotobuki Pharmaceutical Co., Ltd. 72 Kowa Company, Ltd. 73 Kymab Limited 74 LG Life Science LTD. 75 Lipicard Technologies Limited 76 Lotus Pharmaceutical Co., Ltd. 77 Merck & Co., Inc. 78 Nimbus Therapeutics, LLC 79 Nippon Chemiphar Co., Ltd. 80 Pfizer Inc. 81 4
Pharmena SA 82 Prometheon Pharma, LLC 83 Protalix BioTherapeutics, Inc. 84 Sancilio & Company, Inc. 85 Takeda Pharmaceutical Company Limited 86 Thetis Pharmaceuticals LLC 87 Torrent Pharmaceuticals Limited 88 Viking Therapeutics, Inc. 89 Yuhan Corporation 90 Zydus Cadila Healthcare Limited 91 Dyslipidemia - Therapeutics Assessment 92 Assessment by Monotherapy Products 92 Assessment by Combination Products 93 Assessment by Target 94 Assessment by Mechanism of Action 99 Assessment by Route of Administration 102 Assessment by Molecule Type 104 Drug Profiles 106 (amlodipine besylate + atorvastatin + valsartan) - Drug Profile 106 (amlodipine besylate + rosuvastatin calcium + valsartan) - Drug Profile 107 (atorvastatin calcium + hydroxychloroquine sulfate) - Drug Profile 108 (atorvastatin calcium + losartan potassium) - Drug Profile 109 (atorvastatin calcium + metformin hydrochloride) XR - Drug Profile 110 5
(candesartan + rosuvastatin calcium) - Drug Profile 111 (ezetimibe + rosuvastatin calcium) - Drug Profile 112 (gemigliptin + rosuvastatin calcium) - Drug Profile 113 (pitavastatin + valsartan) - Drug Profile 114 (rosuvastatin calcium + metformin SR) - Drug Profile 115 4655-K09 - Drug Profile 116 AEM-28 - Drug Profile 117 AEM-2802 - Drug Profile 118 AEM-2814 - Drug Profile 119 AHRO-001 - Drug Profile 120 ALN-AC3 - Drug Profile 122 ALN-ANG - Drug Profile 123 AMG-899 - Drug Profile 124 anacetrapib - Drug Profile 125 ARI-3037MO - Drug Profile 127 AS-1708727 - Drug Profile 128 AZ-12260493 - Drug Profile 129 BCWPC-001 - Drug Profile 130 bezafibrate ER - Drug Profile 131 BH-03004 - Drug Profile 132 BioE-1115 - Drug Profile 133 bococizumab - Drug Profile 134 BSN-272 - Drug Profile 135 C-24 - Drug Profile 136 6
C-3 - Drug Profile 137 CAT-2000 Series - Drug Profile 138 CAT-2003 - Drug Profile 139 CDR-267F018 - Drug Profile 140 CDX-085 - Drug Profile 141 centatin - Drug Profile 143 CER-209 - Drug Profile 144 CKD-519 - Drug Profile 145 CNX-013B2 - Drug Profile 146 Debio-0930B - Drug Profile 147 DF-461 - Drug Profile 148 DGAT-1 - Drug Profile 149 DPR-212 - Drug Profile 150 DS-8312 - Drug Profile 151 DWJ-1330 - Drug Profile 152 DWJ-1351 - Drug Profile 153 elafibranor - Drug Profile 154 etanercept biosimilar - Drug Profile 157 evolocumab - Drug Profile 158 gemcabene calcium - Drug Profile 161 GSK-2041706 - Drug Profile 162 HCP-1105 - Drug Profile 163 HOB-071 - Drug Profile 164 7
HU-012 - Drug Profile 165 IBI-306 - Drug Profile 166 icosabutate - Drug Profile 167 ISIS-ANGPTL3LRx - Drug Profile 168 ISIS-ANGPTL3Rx - Drug Profile 169 ISIS-APOCIIILRx - Drug Profile 170 JD-2000 Series - Drug Profile 171 JD-5000 Series - Drug Profile 172 JD-5006 - Drug Profile 173 JD-6000 Series - Drug Profile 174 JLP-1302 - Drug Profile 175 JLP-1401 - Drug Profile 176 K-312 - Drug Profile 177 K-877 - Drug Profile 178 KT-6971 - Drug Profile 180 KTA-439 - Drug Profile 181 KY-1020 - Drug Profile 182 leucine + niacin - Drug Profile 183 LP-071 - Drug Profile 184 LT-5421 - Drug Profile 185 LT-5423 - Drug Profile 186 MAT-9001 - Drug Profile 187 MBX-8025 - Drug Profile 188 MGL-3196 - Drug Profile 190 8
NC-2400 - Drug Profile 191 ND-630 - Drug Profile 192 ND-654 - Drug Profile 193 NKPL-66 - Drug Profile 195 Read More http://www.idatainsights.com/reports-landing-page.php?id=179091/dyslipidemia-pipelinereview-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.
9